企業プロフィール
MoonLake Immunotherapeutics 株価・ニュース・カタリスト
- ティッカー:
- MLTX
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- Switzerland
株価パフォーマンス
16.35 USD (-0.73%)
終値
最終更新: 2026年8月17日
1.32B USD
時価総額
株価変動の要因
As of Aug 17, 2026, MLTX closed down 0.73% at $16.35. No new same-company headline was identified in the current news window.
企業概要
Nanobody-Based Immunology
MoonLake Immunotherapeutics develops therapies for inflammatory diseases using Nanobodies, compact antibody-derived proteins designed for tissue penetration, molecular stability and multivalent target binding.
Sonelokimab
Sonelokimab is a trivalent Nanobody that binds IL-17A and IL-17F while also interacting with albumin. MoonLake is developing the candidate across dermatology and rheumatology indications with substantial unmet need.
Hidradenitis Suppurativa
The VELA Phase 3 program evaluated sonelokimab in adults with hidradenitis suppurativa, while VELA-TEEN extends development into adolescents. The adult program supports the company's planned U.S. biologics-license application.
Psoriatic Arthritis
IZAR-1 and IZAR-2 are global Phase 3 studies in active psoriatic arthritis. IZAR-1 met all Week 16 clinical endpoints for the selected sonelokimab regimen, and IZAR-2 includes a standard-of-care comparator in patients who did not respond adequately to TNF inhibitors.
Additional Inflammatory Diseases
MoonLake is also studying sonelokimab in axial spondyloarthritis and preparing a clinical program in palmoplantar pustulosis, extending the franchise across multiple IL-17-driven diseases.
今後のカタリスト
- Completion of enrollment in the Phase 3 IZAR-2 psoriatic-arthritis study in the third quarter of 2026.
- Sonelokimab BLA submission for hidradenitis suppurativa by the end of September 2026.
- Initiation of enrollment in the palmoplantar-pustulosis program in the second half of 2026.
- FDA assignment of a PDUFA date and decision on Priority Review for the hidradenitis-suppurativa BLA by the end of November 2026.
- Results from the P-OLARIS psoriatic-arthritis/axial-spondyloarthritis study at the end of 2026 or in early 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。